Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
I have been trying to see what they have patented - as I understand it this is one of the reasons big pharma have not gone in too heavily on cannaboids.
I can see on Companies House, the CEO has set something up in respect of IP but I cannot find any applications by either that Company or Celadon.
I suspect we may see a few hefty sells later btw.
Https://www.nccih.nih.gov/grants/dea-approved-bulk-cannabis-suppliers
One of these. I note the Europe, the US and other parts of the world comment
Https://www.lse.co.uk/rns/CEL/approval-to-roll-out-chronic-pain-clinical-trial-xw35rpuchuzlw0f.html
He referred to LoI’s being penned. It sounds like they do not have the capacity for another large contract even with Phase II, but he referred to a number of other companies that would fit out their premises to support further awards.
I am more interested in what is happening with the CANPAIN trial - was hardly discussed at the AGM?
Contractors at Zulu have agreed to accept payment of US$2 million dollars of invoices, in new ordinary shares of the Company. Accordingly, the Company has today settled payment of US$2 million (equivalent to £1.57 million) in invoices through the issue of 983,500,000 new ordinary shares of the Company at the price of 0.16 pence per ordinary share ("Settlement Shares"). The Settlement Shares will, when issued, rank pari passu in all respects with the existing ordinary shares.
Eek - come back in July
It's on youtube now - still none the wiser to be honest. Quite a lot of smoke and mirrors - sounds like there is quite a lot of news in the pipeline, but he was saying the same in the Sunday Roast podcast a few months back.
They are definitely in the right space though.
Https://www.cannabiz.com.au/uk-patient-numbers-demand-and-consumption-surge-to-all-time-high/
The approval of the trial protocol, and in particular the data capture and dosage control methodologies, has also led to further exploration of the potential use of the protocol to treat other conditions. Discussions are ongoing with a healthcare provider about a novel application for the protocol.
Be interested to know what those other conditions are and if this will create a material delay to the planned commencement of the main CANPAIN trial?
And this:
On 8 March 2024, the Group disposed of its investment in Harley Street (CPC) Limited for a consideration of £500,000 payable over three years. At the time of the disposal, the only activity conducted by Harley Street (CPC) Limited was the operation of a CQC registered clinic. The assets relating to the CANPAIN Trial had been transferred to Celadon Property Co Limited during 2023.